YOLFTbeta
Polyrizon Ltd. Ordinary Shares

Polyrizon Ltd. Ordinary Shares

PLRZ · NASDAQ · Healthcare / Biotechnology

11.05USD-0.43 (-3.75%)

Price History

Full chart

Market Stats

Previous Close11.48
Open11.00
Day Range10.75 – 11.19
52-Week Range2.88 – 18.20
Volume5.75K
Market Cap24.89M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.71
Dividend Yield0.00%
50-Day Avg11.61
200-Day Avg12.81

About

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Eyal S. Ron Ph.D.
  • Employees2
  • Headquarters5 HaPnina Street, Ra'anana, Israel, 4321545, USA
  • Websitehttps://www.polyrizon-biotech.com

Leadership

  • Dr. Eyal S. Ron Ph.D.Chief Scientific Officer · b. 1955

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0000
Cost of Revenue1.00K6.00K5.00K4.00K118.00K342.00K
Gross Profit-1.00K-6.00K-5.00K-4.00K-118.00K-342.00K
Operating Expense71.00K697.00K890.00K631.00K1.18M5.91M
Operating Income-72.00K-703.00K-895.00K-635.00K-1.30M-6.25M
EBITDA-72.00K-703.00K-772.00K-631.00K-1.42M-5.91M
Net Income-73.00K-711.00K-779.00K-600.00K-1.54M-3.33M
R&D38.00K245.00K347.00K332.00K534.00K2.13M
Interest Expense-2.00K2.00K2.00K3.00K3.14M

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets24.00K687.00K546.00K559.00K5.55M21.44M
Total Liabilities8.00K690.00K1.20M750.00K261.00K443.00K
Total Equity16.00K-3.00K-652.00K57.00K5.29M20.99M
Cash10.00K523.00K36.00K4.00K2.55M1.31M
Total Debt--622.00K200.00K--
Net Debt-10.00K-523.00K-36.00K196.00K-2.55M-1.31M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-73.00K-492.00K-1.13M-537.00K-1.15M-4.53M
Investing Cash Flow-6.00K-19.00K-3.00K-29.00K-16.53M
Financing Cash Flow89.00K1.02M648.00K505.00K3.67M19.81M
Capital Expenditure6.00K19.00K3.00K007.00K
Free Cash Flow-79.00K-511.00K-1.14M-537.00K-1.15M-4.54M
FCF to OCF108.22%103.86%100.27%100.00%100.00%100.15%

Earnings

Report DateMar 11, 2025Sep 17, 2025
EPS Estimate0.000.00
EPS Actual-72.60-0.74
Surprise--
Timing--

Key Statistics & Ratios

Market Cap24.89M
Enterprise Value27.00M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.26
EPS-4.71
Book Value13.05
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-5.91M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-25.38%
Return on Assets-28.95%
Shares Outstanding2.40M
Shares Float1.42M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
9.35%
Insiders
0.73%
Retail / Other
89.92%

Top Institutional Holders

  • Mercer Global Advisors Inc.
    1.67K0.10%
  • Legacy Wealth Managment, LLC/ID
    1.15K0.07%
  • Citigroup Inc
    10.00%
  • Jane Street Group LLC
    00.00%
  • Citadel Advisors Llc
    00.00%
  • UBS Group AG
    00.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    8230.05%

Stock Splits

  • Nov 28, 20251:6
  • May 27, 20251:250